CLYM Climb Bio, Inc.
Price Chart
Executive Summary
Climb Bio announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. Preliminary data from 49 healthy volunteers showed no serious adverse events, dose-limiting toxicities, or discontinuations, with all adverse events mild-to-moderate and self-resolving. The company plans to advance CLYM116 into further development, and partner Mabworks expects to initiate Phase 2 dosing in IgAN patients in Q3 2026.
Actionable Insight
Early safety data is clean but from a small sample (n=49) — not yet de-risking the program. The key catalyst is Phase 2 initiation in IgAN patients by partner Mabworks in Q3 2026. Monitor for efficacy data and any safety signals as dosing expands.
Key Facts
- CLYM116 is an anti-APRIL monoclonal antibody for IgA nephropathy and other immune-mediated diseases.
- Initial Phase 1 safety data from 49 healthy volunteers (single doses up to 320 mg or placebo) showed no SAEs, DLTs, or discontinuations.
- All adverse events were Grade 1-2, transient, and self-resolving; injection site reactions in two patients (Grade 1) resolved without intervention.
- Translational PK/PD model from NHP data projects dose-dependent IgA suppression and potential for less-frequent dosing vs. first-generation anti-APRIL approaches.
- Partner Mabworks expects to initiate Phase 2 dosing in IgAN patients in Q3 2026.
- Global Phase 1 strategy includes parallel healthy volunteer datasets ex-China and China (n=80, doses 25 mg to 640 mg).
Financial Impact
No financial figures disclosed; early-stage clinical data with no revenue or expense impact reported.
Risk Factors
- Small sample size (n=49) limits safety conclusions; larger Phase 2 may reveal new safety signals.
- Translational PK/PD model from NHP data may not predict human efficacy; IgA suppression correlation is literature-based, not from CLYM116 human data.
- Partner-dependent development in China adds execution risk; timelines may slip.
- No financial data or guidance provided; pre-revenue biotech with no near-term revenue catalyst.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-258372 |
| Document: 0001193125-26-258372-index-headers.html | 0001193125-26-258372 |
| Document: 0001193125-26-258372-index.html | 0001193125-26-258372 |
| Document: 0001193125-26-258372.txt | 0001193125-26-258372 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
8-K
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 12, 2026
today
|
424B5
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 10, 2026
3d ago
|
EFFECT
| $11.14 awaiting T+5 | awaiting T+5 | — | $11.44 (+2.69%) |
|
Jun 5, 2026
7d ago
|
8-K
| $10.77 awaiting T+5 | awaiting T+5 | — | $11.44 (+6.22%) |
|
May 29, 2026
14d ago
|
S-3
| $11.80 $10.55 | ▼ −10.59% | ▼ −7.84% | $11.44 (−3.05%) |
|
May 7, 2026
5w ago
|
8-K
| $11.91 $11.41 | ▼ −4.20% | ▼ −5.70% | $11.44 (−3.95%) |
|
May 5, 2026
5w ago
|
8-K
| $11.45 $11.17 | ▼ −2.45% | ▼ −4.43% | $11.44 (−0.09%) |
|
Apr 28, 2026
6w ago
|
8-K
| $9.26 $9.69 | ▼ −4.64% | ▼ −2.95% | $11.44 (−23.54%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $9.50 $9.69 | ▲ +2.00% | ▲ +1.60% | $11.44 (+20.42%) |
|
Apr 3, 2026
10w ago
|
8-K
| $6.74 $8.63 | ▲ +28.04% | ▲ +23.91% | $11.44 (+69.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access